About Cytochrome c oxidase subunit 2
Cytochrome c oxidase subunit 2 (MT-CO2) is a protein
from Homo sapiens identified by UniProt accession
P00403, 227 residues long.
MolForge cross-references it against 0 known binders and
81 disease associations.
Target properties
| Protein name | Cytochrome c oxidase subunit 2 |
|---|
| UniProt accession | P00403 |
|---|
| Gene | MT-CO2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 227 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (81)
Diseases linked to this target (Open Targets).
- mitochondrial disease · score 0.70
- MELAS · score 0.66
- MELAS syndrome · score 0.57
- leigh syndrome due to mitochondrial complex iv deficiency · score 0.54
- mitochondrial complex IV deficiency, nuclear type 22 · score 0.54
- cytochrome-c oxidase deficiency disease · score 0.53
- MERRF syndrome · score 0.51
- MERRF · score 0.51
- mitochondrial non-syndromic sensorineural hearing loss · score 0.49
- inborn mitochondrial myopathy · score 0.49
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P00403-F1 | alphafold | PREDICTED | 94.74 | — |
Amino-acid sequence (227 residues)
MAHAAQVGLQ DATSPIMEEL ITFHDHALMI IFLICFLVLY ALFLTLTTKL TNTNISDAQE METVWTILPA IILVLIALPS LRILYMTDEV NDPSLTIKSI GHQWYWTYEY TDYGGLIFNS YMLPPLFLEP GDLRLLDVDN RVVLPIEAPI RMMITSQDVL HSWAVPTLGL KTDAIPGRLN QTTFTATRPG VYYGQCSEIC GANHSFMPIV LELIPLKIFE MGPVFTL
Explore Cytochrome c oxidase subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets